Multiomic Analysis and CRISPR Perturbation Screens Identify Endothelial Cell Programs and Novel Therapeutic Targets

Rajat M Gupta1,2, Gavin R Schnitzler1,2, Shi Fang1,2

  • 1Divisions of Genetics and Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston MA (R.M.G., G.R.S., S.F., V.S.L.-K., A.B.).

Insights

Endothelial cells (ECs) are key to vascular disease. Multiomic and CRISPR approaches help identify genetic pathways in ECs that cause atherosclerosis, speeding up drug target discovery.

Area of Science:

  • Cardiovascular Biology
  • Genetics
  • Molecular Biology

Background:

  • Endothelial cells (ECs) mediate atherosclerosis and vascular disease.
  • Endothelial dysfunction arises from risk factors like hypertension and high cholesterol.
  • Identifying causal EC functions in disease risk has been challenging.

Purpose of the Study:

  • To review genomic, epigenomic, and transcriptomic data prioritizing EC-specific causal pathways.
  • To highlight how new methods accelerate the characterization of disease-associated genetic variation.
  • To summarize studies using high-throughput genetic perturbation in ECs to identify disease mechanisms.

Main Methods:

  • Review of genomic, epigenomic, and transcriptomic studies.
  • Analysis of human genetics and in vivo models.
  • Application of CRISPR perturbation technology with multiomic analysis.

Main Results:

  • Dysregulation of nitric oxide production is linked to coronary artery disease risk.
  • Multiomic approaches unbiasedly identify causal genetic mechanisms in EC dysfunction.
  • High-throughput genetic perturbation in ECs identifies disease-relevant pathways.

Conclusions:

  • Genetically validated pathways in ECs can accelerate the discovery of drug targets for atherosclerosis.
  • CRISPR technology combined with multiomics speeds up the identification of disease-associated genetic variation.
  • Understanding EC-specific causal pathways is crucial for preventing and treating vascular diseases.